Table 3.
Mutational patterns of ETV and coexist resistance in patients who received sequential/combined nucleos(t)ide analogue therapies
| Drug usage* | Major mutational patterns | n | Drug usage | Major mutational patterns | n |
|---|---|---|---|---|---|
| LAM→ADV (n = 136) | LAM→ADV→ETV (n = 38) | ||||
| ETV‐R | V173L + M204I + M250L | 1 | Coexist‐R | L180M + A181V + M204V | 1 |
| L180M + T184I/L + M204V | 2 | ETV‐R | L180M + S202G + M204V | 5 | |
| V173L + L180M + M204I + M250L | 1 | L180M + T184L/A + M204V | 1 | ||
| Coexist‐R | L180M + A181T + M204I + N236T | 1 | L180M + T184L + M204I/V | 1 | |
| L180M + A181V + M204V + N236T | 1 | L180M + T184S + M204V | 1 | ||
| L180M + A181V + M204I/V | 1 | LAM→ADV→ADV + LdT (n = 2) | |||
| L180M + A181V + M204V | 4 | ETV‐R | L180M + M204I + M250L | 2 | |
| V173L + A181V + M204I | 1 | LAM→LAM + ADV (n = 32) | |||
| A181V + M204I + M250I | 1 | ETV‐R | V173L + M204I + M250L | 1 | |
| LAM→ETV (n = 35) | LAM→LAM + ADV→ADV→ETV (n = 1) | ||||
| ETV‐R | L180M + T184S + M204V | 2 | ETV‐R | L180M + A181G + T184L + M204V | 1 |
| L180M + S202G + M204V | 1 | LAM→LAM + ADV→ETV + ADV (n = 1) | |||
| L180M + T184I + M204I/V | 1 | ETV‐R | L180M + T184I + M204I | 1 | |
| L180M + T184S + M204I | 1 | LAM→LAM + ETV→ETV (n = 1) | |||
| L180M + T184A + M204V | 1 | ETV‐R | L180M + T184L + M204V | 1 | |
| L180M + T184L + S202G + M204V | 1 | ADV→LdT (n = 8) | |||
| M204V + A181S + T184I | 1 | Coexist‐R | L180M + A181V + M204V | 2 | |
| V173L + L180M + T184S + M204I | 1 | ADV→ADV + LAM (n = 2) | |||
| L180M + T184L + M204V | 1 | Coexist‐R | V173L + L180M + A181T/V + M204V | 1 | |
| LAM→ADV→LAM + ADV (n = 5) | ADV→LAM→LAM + ADV (n = 2) | ||||
| Coexist‐R | L180M + M204V + N236T | 1 | ETV‐R | V173L + L180M + M204I + M250L | 1 |
| L180M/I + A181T/V + M204I + M250L | 1 | LAM→ADV→ETV →ADV→ADV + LAM (n = 1) | |||
| Coexist‐R | L180M + A181V + S202G + M204V + N236T | 1 | |||
ETV‐R represents entecavir‐resistant mutations, and Coexist‐R represents coexistence of detectable LAM‐R/ETV‐R and ADV‐R in viral populations.
LAM, lamivudine; ADV, adefovir; ETV, entecavir; LdT, telbivudine.
*Each mono‐ or sequential/combined therapy lasted for ≥3 months.